INT95446

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 2001
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 4
Disease Relevance 1.59
Pain Relevance 0.30

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (PHC2) DNA binding (PHC2)
PHC2 (Homo sapiens)
Pain Link Frequency Relevance Heat
Angina 1 98.80 Very High Very High Very High
ischemia 5 91.00 High High
corticosteroid 6 5.00 Very Low Very Low Very Low
Central nervous system 3 5.00 Very Low Very Low Very Low
cytokine 3 5.00 Very Low Very Low Very Low
cINOD 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hyperoxaluria 3 99.24 Very High Very High Very High
Infarction 1 99.10 Very High Very High Very High
Cv General 3 Under Development 1 98.80 Very High Very High Very High
Cv Unclassified Under Development 2 91.00 High High
Coronary Artery Disease 3 75.88 Quite High
Recurrence 315 70.72 Quite High
Chronic Renal Failure 87 66.88 Quite High
Nephrocalcinosis 3 50.04 Quite High
Disease 162 50.00 Quite Low
Urolithiasis 3 49.20 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
No sustained ventricular arrhythmias, ECG evidence of infarction, or ventricular perforations were observed. phVEGF-2-transfected patients experienced reduced angina (before versus after GTx, 36.2+/-2.3 versus 3.5+/-1.2 episodes/week) and reduced nitroglycerin consumption (33.8+/-2.3 versus 4.1+/-1.5 tablets/week) for up to 360 days after GTx; reduced ischemia by electromechanical mapping (mean area of ischemia, 10.2+/-3.5 versus 2.8+/-1.6 cm(2), P=0.04); and improved myocardial perfusion by SPECT-sestamibi scanning for up to 90 days after GTx when compared with images obtained after control procedure.
Gene_expression (transfected) of phVEGF-2 associated with angina, ischemia and infarction
1) Confidence 0.32 Published 2001 Journal Circulation Section Abstract Doc Link 11331253 Disease Relevance 0.60 Pain Relevance 0.30
Indeed, some patients may present with hyperoxaluria without AGT deficiency, leading to a diagnosis of either PH-2 (glyoxylate reductase/hydroxypyruvate reductase deficiency) or non-PH-1 non-PH-2 where Tx strategy has not been clearly delineated.
Gene_expression (deficiency) of PH-2 associated with hyperoxaluria
2) Confidence 0.05 Published 2009 Journal Pediatr Nephrol Section Body Doc Link PMC2753770 Disease Relevance 0.29 Pain Relevance 0
Indeed, some patients may present with hyperoxaluria without AGT deficiency, leading to a diagnosis of either PH-2 (glyoxylate reductase/hydroxypyruvate reductase deficiency) or non-PH-1 non-PH-2 where Tx strategy has not been clearly delineated.
Gene_expression (diagnosis) of PH-2 associated with hyperoxaluria
3) Confidence 0.05 Published 2009 Journal Pediatr Nephrol Section Body Doc Link PMC2753770 Disease Relevance 0.35 Pain Relevance 0
Indeed, some patients may present with hyperoxaluria without AGT deficiency, leading to a diagnosis of either PH-2 (glyoxylate reductase/hydroxypyruvate reductase deficiency) or non-PH-1 non-PH-2 where Tx strategy has not been clearly delineated.
Gene_expression (diagnosis) of non-PH-2 associated with hyperoxaluria
4) Confidence 0.04 Published 2009 Journal Pediatr Nephrol Section Body Doc Link PMC2753770 Disease Relevance 0.35 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox